ARTICLE | Company News
Optimer completes fidaxomicin NDA submission
December 1, 2010 1:48 AM UTC
Optimer Pharmaceuticals Inc. (NASDAQ:OPTR) completed submission of a rolling NDA to FDA for fidaxomicin to treat Clostridium difficile infection (CDI) and to prevent recurrences of CDI. The company r...